denifanstat (TVB-2640)

News alerts, weekly reports and conference planners

Company:

Ascletis, Sagimet Biosci

Drug class:

FASN inhibitor

Related drugs:

‹

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	TVB-2640 Sensitive: C2 – Inclusion Criteria TVB-2640 Sensitive : C2	TVB-2640 Sensitive: C2 – Inclusion Criteria TVB-2640 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3
KRAS mutation	Breast Cancer	KRAS mutation	Breast Cancer	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3

Associations
(3)